Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE104 in Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Phase 1Recruiting
- Start
- Nov 2025
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of EVOLVE104 in bladder cancer, lung squamous cell carcinoma (LSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 2 more (12 cohorts). Primary endpoints: Incidence and Severity of Treatment Emergent Adverse Events at 10 months, Number of patients with Dose Limiting Toxicities at 10 months and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
EVOLVE104
03
Conditions
bladder cancerlung squamous cell carcinoma (LSCC)Esophageal Squamous Cell Carcinoma (ESCC)cutaneous squamous cell carcinoma (cSCC)Anogenital Squamous Cell Carcinoma
Beyond the preview
Go deeper on NCT07217171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217171.